317 related articles for article (PubMed ID: 28403774)
1. Pharmacogenetics of Aromatase Inhibitors in Endocrine Responsive Breast Cancer: Lessons Learnt from Tamoxifen and CYP2D6 Genotyping.
Baatjes KJ; Conradie M; Apffelstaedt JP; Kotze MJ
Anticancer Agents Med Chem; 2017; 17(13):1805-1813. PubMed ID: 28403774
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Punglia RS; Burstein HJ; Winer EP; Weeks JC
J Natl Cancer Inst; 2008 May; 100(9):642-8. PubMed ID: 18445827
[TBL] [Abstract][Full Text] [Related]
3. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
Regan MM; Leyland-Jones B; Bouzyk M; Pagani O; Tang W; Kammler R; Dell'orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Neven P; Debled M; Maibach R; Price KN; Gelber RD; Coates AS; Goldhirsch A; Rae JM; Viale G;
J Natl Cancer Inst; 2012 Mar; 104(6):441-51. PubMed ID: 22395644
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomics of tamoxifen and aromatase inhibitors.
Ingle JN
Cancer; 2008 Feb; 112(3 Suppl):695-699. PubMed ID: 18072234
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of anti-estrogen treatment of breast cancer.
Del Re M; Michelucci A; Simi P; Danesi R
Cancer Treat Rev; 2012 Aug; 38(5):442-50. PubMed ID: 21917382
[TBL] [Abstract][Full Text] [Related]
6. A Simulation Study to Compare the Treatment Effect of Tamoxifen by CYP2D6 Genotypes and Third-Generation Aromatase Inhibitors.
Park GC; Jung JA; Bae KS; Lim HS
J Clin Pharmacol; 2017 Sep; 57(9):1088-1096. PubMed ID: 28369967
[TBL] [Abstract][Full Text] [Related]
7. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.
Singh MS; Francis PA; Michael M
Breast; 2011 Apr; 20(2):111-8. PubMed ID: 21185724
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of endocrine therapy for breast cancer.
Higgins MJ; Stearns V
Annu Rev Med; 2011; 62():281-93. PubMed ID: 21226615
[TBL] [Abstract][Full Text] [Related]
10. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.
Goetz MP; Sangkuhl K; Guchelaar HJ; Schwab M; Province M; Whirl-Carrillo M; Symmans WF; McLeod HL; Ratain MJ; Zembutsu H; Gaedigk A; van Schaik RH; Ingle JN; Caudle KE; Klein TE
Clin Pharmacol Ther; 2018 May; 103(5):770-777. PubMed ID: 29385237
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomics of endocrine therapy in breast cancer.
Weinshilboum R
Adv Exp Med Biol; 2008; 630():220-31. PubMed ID: 18637494
[TBL] [Abstract][Full Text] [Related]
12. The ethics of CYP2D6 testing for patients considering tamoxifen.
Hartman AR; Helft P
Breast Cancer Res; 2007; 9(2):103. PubMed ID: 17433116
[TBL] [Abstract][Full Text] [Related]
13. [CYP2D6 polymorphisms and tamoxifen: therapeutic perspectives in the management of hormonodependent breast cancer patients].
Barrière J; Formento JL; Milano G; Ferrero JM
Bull Cancer; 2010 Mar; 97(3):311-20. PubMed ID: 20123649
[TBL] [Abstract][Full Text] [Related]
14. Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer.
Brauch H; Schwab M
Br J Clin Pharmacol; 2014 Apr; 77(4):695-703. PubMed ID: 24033728
[TBL] [Abstract][Full Text] [Related]
15. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?
Higgins MJ; Rae JM; Flockhart DA; Hayes DF; Stearns V
J Natl Compr Canc Netw; 2009 Feb; 7(2):203-13. PubMed ID: 19200418
[TBL] [Abstract][Full Text] [Related]
17. Prioritizing pharmacogenetic research: a value of information analysis of CYP2D6 testing to guide breast cancer treatment.
Woods B; Veenstra D; Hawkins N
Value Health; 2011 Dec; 14(8):989-1001. PubMed ID: 22152167
[TBL] [Abstract][Full Text] [Related]
18. CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines.
Drögemöller BI; Wright GEB; Shih J; Monzon JG; Gelmon KA; Ross CJD; Amstutz U; Carleton BC;
Breast Cancer Res Treat; 2019 Feb; 173(3):521-532. PubMed ID: 30411242
[TBL] [Abstract][Full Text] [Related]
19. A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?
Hayes DF; Stearns V; Rae J; Flockhart D;
J Natl Cancer Inst; 2008 May; 100(9):610-3. PubMed ID: 18445818
[No Abstract] [Full Text] [Related]
20. Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen.
Chan CWH; Law BMH; So WKW; Chow KM; Waye MMY
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1395-1404. PubMed ID: 32270286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
